Lupin obtains FDA nod for generic Alphagan P
Brimonidine Tartrate Ophthalmic Solution, 0.1%, is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The Food and Drug Administration has granted permission to Lupin for Brimonidine Tartrate Ophthalmic Solution, 0.1%, which is a generic of AbbVie’s Alphagan P Ophthalmic Solution.
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
[Read more: Lupin receives FDA nod for generic Lotemax]
This product will be manufactured at Lupin’s Pithampur facility in India.
Brimonidine Tartrate Ophthalmic Solution had a market value of roughly $178.5 million, per June 2024 IQVIA data.
[Read more: Lupin receives FDA nod for 3 generics]